{"id":"NCT03831880","sponsor":"Pfizer","briefTitle":"Patient Perception of Treatment Burden in Weekly Versus Daily Growth Hormone Injections in Children With GHD","officialTitle":"A PHASE 3, RANDOMIZED, MULTICENTER, OPEN-LABEL, CROSSOVER STUDY ASSESSING SUBJECT PERCEPTION OF TREATMENT BURDEN WITH USE OF WEEKLY GROWTH HORMONE (SOMATROGON) VERSUS DAILY GROWTH HORMONE (GENOTROPIN (REGISTERED)) INJECTIONS IN CHILDREN WITH GROWTH HORMONE DEFICIENCY","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2019-02-07","primaryCompletion":"2020-08-28","completion":"2020-08-28","firstPosted":"2019-02-06","resultsPosted":"2021-10-14","lastUpdate":"2021-10-14"},"enrollment":87,"design":{"allocation":"RANDOMIZED","model":"CROSSOVER","masking":"NONE","primaryPurpose":"OTHER"},"conditions":["Growth Hormone Deficiency"],"interventions":[{"type":"DRUG","name":"Genotropin","otherNames":[]},{"type":"DRUG","name":"somatrogon","otherNames":[]}],"arms":[{"label":"Daily to Weekly","type":"OTHER"},{"label":"Weekly to Daily","type":"OTHER"}],"summary":"This is an open label randomized 24 week crossover trial assessing the treatment burden of a weekly growth hormone injection regimen (somatrogon) compared to a daily growth hormone injection regimen (Genotropin). Approximately 90 children with growth hormone deficiency who have been stable on treatment with daily Genotropin will be enrolled.","primaryOutcome":{"measure":"Total Score Related to Overall Life Interference Assessed at Baseline, Using Dyad Clinical Outcomes Assessment 1 (DCOA 1) Questionnaire","timeFrame":"Baseline","effectByArm":[{"arm":"Daily Genotropin Then Weekly Somatrogon","deltaMin":29.5,"sd":18},{"arm":"Weekly Somatrogon Then Daily Genotropin","deltaMin":27.1,"sd":19.8}],"pValues":[]},"eligibility":{"minAge":"3 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":32,"countries":["United States","Bulgaria","Czechia","Slovakia","United Kingdom"]},"refs":{"pmids":[],"seeAlso":["https://pmiform.com/clinical-trial-info-request?StudyID=C0311002"]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":86},"commonTop":["Injection site pain","Injection site haematoma","Nasopharyngitis","Headache","Pyrexia"]}}